TX01
TX01 is a new formulation of a compound already approved for the treatment of rare neurological diseases.
This formulation, developed by Theranexus, has been licensed to the company Exeltis / Insud Pharma. As part of this agreement, Exeltis obtains exclusive marketing and distribution rights for Theranexus' patented product in key regions, including the European Union, the United Kingdom, Latin America and certain countries in the Middle East. This collaboration specifically targets Gaucher and Niemann-Pick type C diseases.